Journals / Ankara Üniversitesi Tıp Fakültesi Mecmuası / 2016 / Cilt: 69 - Sayı: 1

Ga-68 DOTATATE Positron Emission Tomography Computed Tomography Findings in Patients with Neuroendocrine Tumor Suspicion

Nöroendokrin Tümör ?üphesi Olan Hastalarda Ga-68 DOTATATE Pozitron Emisyon Tomografisi/Bilgisayarl Tomografi Bulgular

Pages
7–10
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It can be used for searching possible NET in patients with suspicion.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: We aimed to retrospectively evaluate the outcome of patients with suspected neuroendocrine tumor (NET)s who underwent Ga-68 DOTATATE Pozitrun Emission Tomography/Computed Tomography (PET/CT) imaging and to describe the value of Ga-68 DOTATATE PET/CT in the detection of NETs.
📊
Key Findings & Data:Material and Method: Ga-68 DOTATATE PET/CT images of 35 patients (26M; 9F, mean age; 45.2±5.4 years) with suspected NET were analyzed retrospectively.
💡
Conclusion & Impact:It can be used for searching possible NET in patients with suspicion.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: We aimed to retrospectively evaluate the outcome of patients with suspected neuroendocrine tumor (NET)s who underwent Ga-68 DOTATATE Pozitrun Emission Tomography/Computed Tomography (PET/CT) imaging and to describe the value of Ga-68 DOTATATE PET/CT in the detection of NETs. Material and Method: Ga-68 DOTATATE PET/CT images of 35 patients (26M; 9F, mean age; 45.2±5.4 years) with suspected NET were analyzed retrospectively. Suspicion of NET was due to clinical symptoms (n:12), elevated biochemical markers (n:19) and/or radiological findings (n:13). Clinical/imaging follow-up and/or histopathological confirmation was used as reference standard. Results: Based on the reference standard 13 of 35 patients had NET. Ga-68 DOTATATE PET/CT was positive in 12 out of 13 patients and it was false negative in 1 patient. Pancreas was the commonest site of the primary tumor. Ga-68 DOTATATE was TP(true pozitive), FP (False Positive), TN (True Negative) and FN (False Negative) in, 12, 2, 20 and 1, patients respectively. Sensitivity, specificity, Pozitive Pedictive Value (PPV), Negative Pedictive Value (NPV), and accuracy of Ga-68 DOTATATE PET/CT was calculated as 85%, 95%, 92%, 90% and 91%, respectively. Conclusion: Ga-68 DOTATATE PET/CT has a high accuracy in the detection of suspected NET. It can be used for searching possible NET in patients with suspicion.

Özet

Amaç: Nöroendokrin Tümör (NET) Lüphesi ile Ga-68 DOTATATE Pozitron Emisyon Tomografisi/Bilgisayarl Tomografi (PET/BT) görüntüleme yap lan hastalar n sonuçlar n retrospektif olarak de?erlendirmeyi ve NET saptanmas nda Ga68 DOTATATE PET/BT'nin yerini tan mlamay amaçlad k. Gereç ve Yöntem: Nöroendokrin tumor Lüphesi ile Ga-68 DOTATATE PET/BT yap lan 35 hastan n (26E; 9K, ort. yaL; 45.2±5.4) sonuçlar retrospektif olarak analiz edildi. Nöroendokrin tumor Lüphesi klinik bulgular (n:12), biyokimyasal parametrelerde yükselme (n:19) ve radyolojik bulgular (n:13) idi. Klinik/radyolojik takip ve/veya histopatolojik inceleme referans standart olarak kullan ld . Bulgular: Referans standart temel al narak 35 hastan n 13'ü NET olarak kabul edildi. Ga-68 DOTATATE PET/BT 13 hastan n 12'sinde pozitif ve 1'inde yalanc negative idi. En s k primer tümör lokalizayonu pankreas idi. Ga-68 DOTATATE PET/BT 12, 2, 20 and 1 hastada s ras ile Gerçek Pozitif (GP), Yalanc Pozitif (YP), Gerçek Negatif (GN) ve Yalanc Negatif (YN) idi. Ga-68 DOTATATE PET/BT için duyarl l k, özgüllük, pozitif pediatrig de?er, negatif pediatrik de?er ve do?ruluk s ras ile %85, %95, %92, %90 ve %91% olarak hesapland . Sonuç: Ga-68 DOTATATE PET/BT NET Lüphesinde tümör oda? n n saptanmas nda yüksek do?rulu?a sahiptir ve bu amaçla kullanlabilir.

🔖

Cite This Article

KÜÇÜK, Ö. N., SOYDAL, Ç., BALİ, E., KIR, M. K., ÖZKAN, E. (2022). Ga-68 DOTATATE Positron Emission Tomography Computed Tomography Findings in Patients with Neuroendocrine Tumor Suspicion. Ankara Üniversitesi Tıp Fakültesi Mecmuası, Cilt: 69 - Sayı: 1, 7–10. https://ajindex.com/articles/443728

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25:458-511
  2. Oberg K, Akerström G, Rindi G, Jelic S; ESMO Guidelines Working Group. Neuroendocrinegastroenteropancreatictu mours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2010 May;21Suppl 5: 223-7/227
  3. Modlin IM, Gustafsson BI, Moss SF, et al. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.Ann SurgOncol. 2010;17:2427-2443
  4. Alexandraki KI, Kaltsas G. Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.Endocrine. 2012;41:40-52
  5. Naswa N, Sharma P, Kumar A, et al. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study.AJR Am J Roentgenol. 2011;197:1221-1228
  6. Kowalski J, Henze M, Schuhmacher J, et al. Evaluation of positron emission tomography imaging using [68Ga]- DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.Mol Imaging Biol. 2003;5:42-48
  7. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.J Nucl Med. 2007;48:508-518
  8. Adams S, Baum R, Rink T, et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.Eur J Nucl Med. 1998;25:79-83 9. Ambrosini V, Campana D, Bodei L, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors.J Nucl Med. 2010;51:669-673 10. Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.Eur J Nucl Med Mol Imaging. 2007;34:1617-1626
  9. Haug AR1, Cindea-Drimus R, Auernhammer CJ, et al. The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors.J Nucl Med. 2012;53:1686-1692
  10. Modlin IM, Gustafsson BI, Moss SF, et al. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 2010;17:2427-2443
  11. Spadaro A, Ajello A, Morace C, et al. Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits. World J Gastroenterol. 2005;11:1987- 1990
  12. Malaguarnera M, Cristaldi E, Cammalleri L, et al. Elevated chromogranin A (CrA) serum levels in the patients with advanced pa